01 — OverviewWhat is GLP-1? The Gut Hormone Explained

Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone secreted primarily by L-cells in the small and large intestine in response to food intake. It plays a central role in glucose homeostasis, appetite regulation, and metabolic signalling — acting on receptors distributed throughout the pancreas, brain, heart, kidneys, lungs, and gut.

The hormone was first characterised in the 1980s through the work of researchers Joel Habener and Svetlana Mojsov, a discovery that earned the 2024 Lasker~DeBakey Clinical Medical Research Award — one of the most prestigious honours in biomedicine. Their foundational work identified GLP-1(7-37) as a potent stimulator of insulin release, launching decades of pharmacological research.

In its natural form, GLP-1 has a very short half-life of just 1–2 minutes, rapidly degraded by the enzyme DPP-4. This biological limitation drove decades of research into longer-acting synthetic analogues — ultimately producing compounds like semaglutide that retain GLP-1's core signalling properties across days rather than minutes. GLP-1 peptides are supplied by Atlas Labs Research as research-grade compounds for in vitro laboratory investigation only.

02 — Compound ProfileWhat is Semaglutide? GLP-1's Long-Acting Analogue

Semaglutide is a synthetic, long-acting analogue of GLP-1, engineered by modifying the native peptide with a fatty acid side chain that binds to albumin in plasma — dramatically extending its half-life and enabling prolonged receptor activation. It shares approximately 94% structural homology with native human GLP-1.

In research literature, semaglutide has become the most extensively studied GLP-1 receptor agonist, generating a vast body of data across metabolic, cardiovascular, hepatic, renal, pulmonary, and neurological research domains. Its structural stability and potent receptor binding affinity make it a widely used reference compound in GLP-1 receptor biology research.

03 — ScienceHow GLP-1 & Semaglutide Work: Mechanism of Action

GLP-1 and its analogues operate through a well-characterised G-protein-coupled receptor (GLP-1R), with downstream effects spanning multiple organ systems. The following core mechanisms have been identified across published research.

Glucose-Dependent Insulin Secretion

GLP-1 stimulates insulin release from pancreatic beta cells in a glucose-dependent manner — meaning it enhances insulin output only when blood glucose is elevated, making it fundamentally different from older secretagogues. Simultaneously, it suppresses glucagon release from alpha cells, reducing hepatic glucose output.

Central Appetite & Energy Regulation

GLP-1 receptors are expressed throughout the brain, including the hypothalamus, brainstem, and reward circuits. Research has shown that GLP-1 agonism activates anorexigenic POMC/CART neurons while inhibiting orexigenic NPY/AgRP neurons in the arcuate nucleus. Preclinical studies demonstrate that restricting GLP-1 drug action to the brain alone still produces reduced food intake — confirming appetite suppression as fundamentally brain-mediated.

Gastric Emptying Delay

GLP-1 slows gastric emptying, extending the time food remains in the stomach and prolonging satiety signals. This peripheral mechanism also blunts postprandial glucose spikes — making it a valuable tool in metabolic and gastroenterological research models.

Cardiovascular & Anti-Inflammatory Signalling

GLP-1 receptors are expressed in cardiac muscle, vascular endothelium, and immune cells. Research has documented direct anti-inflammatory, anti-atherosclerotic, and cardioprotective effects in preclinical models — including reductions in oxidative stress markers independent of weight-related effects.

Renal & Hepatic Pathways

Emerging research documents GLP-1R expression in the kidneys and liver, with preclinical data suggesting anti-fibrotic, anti-inflammatory, and metabolic regulatory effects in both organ systems — active areas of investigation in nephrology and hepatology research models.

04 — LiteratureKey Research Findings by Domain

Published research on GLP-1 and semaglutide spans an unusually broad range of scientific disciplines. The following summarises the most significant areas of documented laboratory and clinical research activity:

• ⚖️Metabolic & Obesity Research: Clinical trials using semaglutide 2.4 mg (STEP programme) demonstrated mean body weight reductions of up to 15.2% over 68 weeks. Oral semaglutide (25 mg) produced approximately 13.7% weight loss over 64 weeks in the OASIS 4 trial.
• ❤️Cardiovascular Research: The landmark SELECT trial — 17,604 participants with obesity but without diabetes — found a 20% relative risk reduction in major adverse cardiovascular events (MACEs) with semaglutide. A meta-analysis of 13 cardiovascular outcome trials across 83,258 patients confirmed significant reductions in MACEs, cardiovascular mortality, and stroke.
• 🫀Type 2 Diabetes Research: The SUSTAIN and PIONEER trial programmes extensively documented semaglutide's superiority over other GLP-1 receptor agonists in HbA1c reduction and fasting glucose control across both injectable and oral formulations.
• 🫁Liver Biology (MASH/NASH): The ESSENCE trial found semaglutide 2.4 mg produced resolution of steatohepatitis without worsening fibrosis in 62.9% of patients with biopsy-confirmed MASH, compared to 34.3% with placebo.
• 🧠Neuroscience & Neuroprotection: GLP-1 receptors have been identified in the parietal cortex, hypothalamus, and medulla. Ongoing research investigates GLP-1 agonism in models of neurodegeneration, neuroinflammation, Parkinson's disease, and cognitive ageing.
• 🦴Musculoskeletal Research: The STEP-9 trial documented significant pain score improvements in knee osteoarthritis models. A 2024 Science paper identified a novel gut–joint axis involving GLP-1-mediated bile acid metabolism as a relevant mechanism.
• 🫧Respiratory Research: A meta-analysis of 28 randomised controlled trials (77,485 participants) found GLP-1 receptor agonists associated with a 14% lower risk of respiratory disease, with semaglutide showing the strongest protective signal (RR 0.82).
• 🧪Addiction & Reward Pathway Research: Emerging 2025 data from randomised controlled trials suggest GLP-1 agonism may modulate reward circuitry relevant to alcohol and substance use disorder biology — a rapidly growing area of neuroscience investigation.

05 — DataLandmark Scientific Studies at a Glance

The following table summarises pivotal published research that has defined scientific understanding of GLP-1 and semaglutide:

06 — FrontiersFrontier Research & Future Directions

Next-Generation Multi-Receptor Agonists

Researchers are actively investigating dual and triple receptor agonist compounds combining GLP-1 activity with GIP, glucagon, and other metabolic receptor targets. Retatrutide — a triple GIP/GLP-1/glucagon agonist — demonstrated up to 28.7% weight loss in early-phase TRIUMPH-4 trial data.

Neurodegeneration & Cognitive Research

GLP-1 receptors in the brain have made semaglutide and GLP-1 analogues compelling tools for neuroscience research. Active investigations include models of Parkinson's disease, Alzheimer's pathology, multiple sclerosis, and idiopathic intracranial hypertension — predominantly preclinical research programmes.

Addiction & Reward Circuit Biology

Multiple 2025 randomised controlled trials have documented associations between GLP-1 receptor agonism and reduced alcohol, opioid, and substance use-related outcomes. Researchers hypothesise that GLP-1R modulation of mesolimbic dopamine circuits underlies these observations.

Kidney & Renal Biology

The FLOW trial demonstrated a 24% reduction in major kidney events with semaglutide 1 mg in a high-risk population — generating significant interest in GLP-1 receptor biology including anti-fibrotic and anti-inflammatory mechanisms in nephrology research models.

Oral & Non-Peptide Delivery Research

Advances in oral GLP-1 delivery — including the SNAC technology platform in oral semaglutide formulations and the first non-peptide small-molecule GLP-1 receptor agonist, orforglipron — are generating new pharmacology and bioavailability research questions relevant to peptide delivery science.

07 — SafetyResearch Safety Profile & Handling Notes

Published literature on GLP-1 peptides and semaglutide includes an extensive safety dataset accumulated across large-scale clinical programmes. As research-grade compounds, they are handled in accordance with standard laboratory chemical safety protocols.

08 — SummaryConclusion

GLP-1 and its synthetic analogues represent one of the most significant advances in modern peptide biochemistry and metabolic science. From a short-lived gut hormone first characterised in the 1980s, GLP-1 research has expanded to encompass cardiovascular, neurological, hepatic, renal, musculoskeletal, pulmonary, and addiction biology — all within a remarkably short period of intensive scientific investigation.

Semaglutide, as the most clinically and preclinically studied GLP-1 receptor agonist, has become a reference standard in GLP-1 receptor pharmacology research. Its broad receptor distribution, well-defined pharmacokinetics, and pleiotropic biological effects make it a uniquely versatile research tool for investigators working across metabolic, inflammatory, and neurological research domains.

Atlas Labs Research is proud to support this work by supplying high-quality, research-grade GLP-1 peptide compounds to qualified laboratory investigators advancing this important area of scientific enquiry.